BIOBOHEMIA

This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use.

I accept

Shortlist of cellular cancer vaccines proposed for the upgrade according to antigenic essence technology

Shortlist is also available for download in pdf format.

Download shortlist

1;CancerVax (John Wayne Cancer Institute);Administration of 3 allogeneic melanoma cell lines (M10-V, M24-V, and M101-V pooled in equal amounts) with BCG. Median OS: 12.9 months.;Colon;I;Habal, Gupta, et al. [1] 2;OncoVax (Vaccinogen Inc);Vaccination with autologous colon cancer cells mixed with live BCG. Significant improvement in overall and disease-free survival in IIIa study.;Colon;III;Vermorken, Claessenet , et al. [2]. NCT02448173 3;ONYCR1-3 (ONYvax);Allogeneic adenocarcinoma cell-based vaccines mixed with BCG or alum adjuvant.;Colon;I/II;NCT00007826 (Arm II and III) 4;HyperAcute-Breast cancer (NewLink Genetics Corporation);Genetically modified allogeneic tumor cells expressing the xenoantigen αGal.;Breast;I/II;NCT00090480 5;Allogeneic GM-CSF-secreting whole-cell breast cancer vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins);The GMCSF–producing 3SKBR3-7 and 2T47D-V cells combined into a single vaccine formulation.;Breast;I;Emens, Armstrong, et al. [3] 6;Allogeneic cellular cancer vaccine (Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute);Vaccination with MDA-MB-231, an HLA-A2(+), HER2/neu(+) allogeneic breast cancer cell line genetically modified to express the costimulatory molecule CD80 (B7-1).;Breast;I;Dols, Smith, et al. [4]. 7;Allogeneic cellular cancer vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, NCI);Allogeneic GM-CSF-secreting breast cancer cell lines (SKBR3 and T47D) alone or with CY and DOX.;Breast;I;Emens, Asquith, et al. [5]. NCT00093834. 8;Allo GM-CSF-secreting vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins);Allogeneic GM-CSF-secreting breast cancer vaccine (two parts 2T47D-V and one part 3SKBR3-7) plus Trastuzumab and Cyclophosphamide.;Breast;II;Chen, Gupta, et al. [6]. NCT00399529. 9;KS2422-vacc (University Hospital Tuebingen, Paul Ehrlich Institute, Langen, Germany);Allogeneic breast cancer cell line, KS24.22, genetically modified to express CD80 and Her-2/neu.;Breast;I;Gückel, Stumm, et al. [7]. NCT01127074. 10;BriaVax (BriaCell Therapeutics Corpjration);BriaVax is derived from a human breast cancer cell line (SV-BR-1-GM) that expresses the protein Her2/neu, which is overexpressed in some epithelial cancers like breast and ovarian cancers. It was designed to produce and secrete GM-CSF.;Breast, Ovary;I/II;NCT03066947. 11;O-Vax (AVAX Technologies);DNP-Modified Autologous Ovarian Tumor Cell Vaccine. Median OS: 22.7 months.;Ovary;I/ II;Berd, Sato, et al. [8], NCT00660101. 12;Autologous DC vaccine (Edward Hirschowitz, University of Kentucky, NCI);Autologous dendritic cells loaded with allogeneic non-small cell lung cancer cells (NSCLC cell lines that over-expresses Her2/neu, CEA, WT1, Mage2, and survivin).;Lung;II;Hirschowitz, Foody, et al. [9]. NCT0010311. 13;MelCancerVac (Herlev Hospital, University of Copenhagen);Autologous dendritic cells pulsed with allogeneic melanoma cell lysate (MelCancerVac) in combination with the Cox-2 inhibitor of celecoxib.;Lungl;II;NCT00442754. 14;HyperAcute-Lung Cancer (tergenpumatucel-L) (NewLink Genetics Corporation, NCI);Vaccine consists of genetically modified allogeneic NSCLC tumor cells with the αGal moiety on the cell surfaces.;Lung;I/II;Pruitt, Kirk, et al. [10]. Lai, Kolber-Simonds, et al. [11]. NCT00073398. 15;1650-G Vaccine (University of Kentucky);Allogeneic NSCLC cell line 1650 mixed with GM-CSF.;Lung;I/II;Hirschowitz, Mullins, et al. [12]. NCT00654030. 16;Viagenpumatucel-L (HS-110) (Heat Biologics);Allogeneic vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig.;Lung;I/II;NCT02117024. 17;GVAX lung cancer vaccine (Southwest Oncology Group, NCI);K562 cells genetically modified to secrete GM-CSF combined with autologous lung tumor cells. Median OS: 5.4 months.;Lung;I/II;Nemunaitis, Jahan, et al. [13]. NCT00074295. 18;Belagenpumatucel-L (Lucanix) (NovaRx Corporation);Administration of Belagenpumatucel-L (a cocktail of 4 irradiated allogeneic NSCLC cell lines transfected with TGF-β2 antisense transgene). Median OS in II trial: 14.5 months.;Lung;II/III;Nemunaitis, Dillman et al. [14]. Nemunaitis, Nemunaitis, et al. [15]. Giaccone, Bazhenova, et al. [16] NCT01058785. NCT00676507. 19;Allogeneic tumor cell-based vaccine (H. Lee Moffitt Cancer Center and Research Institute, NCI, NIH);Allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF.;Lung;II;NCT00601796. 20;Allogeneic B7.1/HLA-A1 (University of Miami);Administration of irradiated whole-cell (AD100) allogeneic vaccine transfected to express B7.1 along with either HLA-A1 or HLA-A2. Median OS: 18 months.;Lung;I/II;Raez, Cassileth, et al. [17]. NCT00534209. 21;Allogeneic vaccine (University of Miami);Allogeneic tumor cells secreting endoplasmic reticulum-chaperone gp96-Ig-peptide complexes. Median OS: 16.5 months.;Lung;I;Raez, Walker, et al. [18]. 22;CanVaxin (CancerVax Corporation);Allogeneic whole-cell vaccine consisting of three melanoma lines combined with BCG as an adjuvant. In phase II median OS and 5-year rate of survival were significantly higher in stage III melanoma.;Melanoma;III;NCT00052156, NCT00052130. 23;Melacine (Corixa Corporation);Administration of Mel-D and Mel-S cell lysates (Melacine) with DETOX.;Melanoma;I;Mitchell, Kanmitchell, et al. [19]. 24;Melacine (Corixa Corporation);Administration of Melacine with CY and IFN-α i.v. after 4 doses of Melacine. Median OS: 12.5 months.;Melanoma;II/III;Vaishampayan, Abrams, et al. [20]. 25;Melacine (Corixa Corporation);Melacine administration. Investigation of the impact of class I antigen expression on relapse-free survival after adjuvant therapy with the vaccine (5 years relapse-free survival).;Melanoma;III;Sosman, Unger, et al. [21]. 26;Autologous DC vaccine (Centro de Investigaciones Oncológicas FUCA et al.);Ex vivo loading of autologous DCs with antigens from apoptotic/necrotic allogeneic melanoma cells and subsequent adoptive transfer. Apoptotic-necrotic (Apo-Nec) tumor cells were prepared as a batch of four cell lines (MEL-XY1, MEL-XY2, MEL-XY3 and MEL-XX4).;Melanoma;I;Von Euw, Barrio, et al. [22]. 27;A2/4-1BBL melanoma vaccine (Hadassah Medical Organization);Vaccination with irradiated M20/A2B cells.;Melanoma;I/II;NCT01898039. 28;VACCIMEL (CSF-470 vaccine) (Laboratorio Pablo Cassará S.R.L. et al.);Administration of Cyp followed by VACCIMEL (a mixture of 3 allogeneic cell lines IIB-MEL-J, IIB-MEL-LES, and IIB-MEL-IAN).;Melanoma;II/III;Mordoh, Kairiyama, et al. [23]. NCT01729663. 29;VACCIMEL (CSF-470 vaccine) (Laboratorio Pablo Cassará S.R.L. et al.);Administration of VACCIMEL with rhGM-CSF.;Melanoma;I;Barrio, De Motta, et al. [24]. 30;Dendritic cell vaccine (Baylor Institute for Immunology Research);Administration of autologous monocyte-derived DCs loaded ex vivo with killed allogeneic Colo829 melanoma cells and activated with GM-CSF, IL-4, TNF-α and CD40 ligand. Median OS: 22.5 months.;Melanoma;I;Palucka, Ueno, et al. [25]. 31;BIBW2 component A and B (Boehringer Ingelheim);Allogeneic tumor vaccine BIWB 2 Containing Melanoma Cells Transfected With the Human IL-2 Gene.;Melanoma;I;NCT02203864. 32;M-Vax (DNP-VACC) (AVAX Tech.);DNP-modified autologous tumor cells. 5-year OS rate was 46%.;Melanoma;I/II;David Berd [26]. 33;Autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine (Jonsson Comprehensive Cancer Center, NCI);Matured dendritic cells pulsed ex vivo with 3 melanoma cell line lysates (IDD-3).;Melanoma;II;Ribas, Camacho, et al. [27]. NCT00107159. 34;CSF470 Vaccine (Laboratorio Pablo Cassará S.R.L.);Allogeneic 4 lethally-irradiated cutaneous melanoma cell lines (MEL-XY1, MEL-XY2, MEL-XY3, and MEL-XX4).;Melanoma;II/III;Aris, Bravo, et al. [28]. Mordoh, Pampena, et al. [29]. NCT01729663. 35;GVAX (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins);Allogeneic pancreatic tumor cells transfected with a GM-CSF gene administered in combination with Ipilimumab (an antibody that blocks negative signals to T cells).;Pancreas;I;Le, Lutz, et al. [30]. Hopkins, Yarchoan, et al. [31]. 36;PANC 10.05 and PANC 6.03 vaccines (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Viragh Foundation);A pancreatic vaccine secreting a GM-CSF and consists of equal numbers of pancreatic cancer cells (Panc 6.03) and (Panc 10.05) into a single vaccine.;Pancreas;II;NCT01088789. 37;GVAX (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, NCI);Allogenic pancreatic tumor cell vaccine transfected with GM-CSF used with cyclophosphamide.;Pancreas;II;NCT00727441. 38;GVAX;Irradiated GM-CSF transfected allogeneic whole-cell tumor lines. Two pancreas cancer cell lines (PANC 10.05 and PANC 6.03) were combined. The median disease-free survival is 17.3 months with a median OS of 24.8 months.;Pancreas;I/II;Lutz, Yeo, et al. [32]. NCT00084383. 39;GVAX;First administration of an allogeneic prostate cancer cell lines (PC3 and LNCap) modified to secrete GM-CSF.;Prostate;I/II;Simons, Carducci et al. [33]. 40;GVAX;Administration of allogeneic prostate cancer cell lines (PC3 and LNCap) modified to secrete GM-CSF. Median OS: 34.9 months (high dose), 24.0 months (low dose).;Prostate;I/II;Small, Sacks, et al. [34]. 41;GVAX;Administration of GVAX plus Ipilimumab (fully human IgG CTLA-4 blocking Ab). Median OS: 29.2 months.;Prostate;I;Van den Eertwegh, Versluis et al [35]. 42;GVAX;Administration of 2 allogeneic prostate-carcinoma cell lines (PC3 and LNCap) modified to secrete GM-CSF. Median OS: 35.0 months (high-dose), 20.0 months (mid-dose), 23.1 months (low-dose).;Prostate;I/II;Higano, Corman, Smith, et al. [36]. 43;ONY-P1 (ONYVAX-P) (Kael-GemVax Co., Ltd, NCI);Vaccine is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer.;Prostate;II;Doehn, Torsten et al. [37]. NCT00514072. 44;Allogeneic vaccine (Institut für Experimentelle Onkologie und Therapieforschung);Administration of LNCaP modified using retroviral vector to secrete IL-2 and IFN-γ. Median OS: 32 months.;Prostate;I/II;Brill, Kuebler et al. [38]. Brill, Kuebler Pohla, et al. [39]. 45;Allogeneic whole-cell vaccine (OnyVax Ltd);Administration of whole-cell vaccine consisting of a mixture of 3 prostate cancer cell lines (Pr1-4) along with Mycobacterium vaccine (SRL172).;Prostate;I/II;Eaton, Perry, et al. [40]. 46;Neuroblastoma vaccine (Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine);Vaccination with unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells.;Brain;;NCT01192555. 47;Gliovac (ERC1671) (Daniela A. Bota, University of California, Epitopoietic Research Corporation);Autologous and allogeneic tumor cell vaccines against glioblastoma based on irradiated DNFB-modified tumor cells.;Brain;II;Schijns, Pretto, et al. [41]. NCT01903330. 48;Autologous DC vaccine (Mayo Clinic, NCI);Allogeneic glioma tumor lysate-pulsed autologous dendritic cell vaccine.;Brain;I;NCT03360708. 49;DC-APCC (Mayo Clinic, NCI);Allogenic whole prostate carcinoma cell (APCC) vaccine co-administered with ex vivo generated dendritic cells.;;II;NCT00814892. 50;RCC26/IL-7/CD80 vaccine (Charite´-University Medicine et al.);Administration of renal cancer cell line (RCC26) genetically modified to express IL-7 and CD80 (B7-1). Median OS: 40 months.;Kidney;I;Westermen, Flörcken, et al. [42]. 51;MGN1601 (Mologen AG);Genetically modified allogeneic tumor cells for the Expression of IL-7, GM-CSF, CD80, and CD154.;Kidney;I/II;NCT01265368. 52;Allogeneic myeloma GM-CSF Vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CellGen Corporation);Allogeneic GM-CSF secreting myeloma vaccine in combination with lenalidomide.;Blood;II;NCT01349569. 53;K562/GM-CSF vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cell Genesis Inc);Vaccine produced from chronic myeloid leukemia (CML) cell line modified to secrete GM-CSF administered with imatinib mesylate.;Blood;I;Smith, Kasamon, et al. [43]. 54;Allogeneic tumor cell vaccine (K562) (NCI);Allogeneic tumor cell vaccine produced from cell line K562.;Lung, Esophagus, Pleura, Thymus;I;NCT01143545. 55;ADKV (N.N. Petrov National Medical Research Center of Oncology);Autologous dendritic cell vaccine (ADKV) loaded with allogeneic tumor lysate expression of cancer-testis antigens (CTA).;Soft tissue sarcomas;I/II;NCT01883518. 56;Allogenic tumor cell vaccine (K562) (NCI, NIH Clinical Center); Vaccine produced from irradiated K562 erythroleukemia cells expressing GM-CSF (K562-GM cells).;Sarcoma, Melanoma, Epithelium, Pleura;I;NCT01313429. 57;Tumor cell vaccine (Hadassah Medical Organization, International Center for Cell Therapy & Cancer Immunotherapy);Vaccination with allogeneic tumor cell lines that share MHC determinants with the patient aiming to overcome the possible restriction of antigen presentation.;Solid tumors;II;NCT00148993. 58;Antiangiogenic cancer vaccine (University of Tokyo);Vaccine using glutaraldehyde-fixed human umbilical vein endothelial cells (HUVECs).;Brain, Colon;I;Okaji et al. [44].

References

1. Habal, N.; Gupta, R.K.; Bilchik, A.J.; Yee, R.; Leopoldo, Z.; Ye, W.; Elashoff, R.M.; Morton, D.L. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann. Surg. Oncol. 2001, 8, 389–401.

2. Vermorken, J.B.; Claessen, A.M.E.; Van Tinteren, H.; Gall, H.E.; Ezinga, R.; Meijer, S.; Scheper, R.J.; Meijer, C.J.L.M.; Bloemena, E.; Ransom, J.H.; et al. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 1999, 353, 345–350.

3. Emens, L.A.; Armstrong, D.; Biedrzycki, B.; Davidson, N.; Davis-Sproul, J.; Fetting, J.; Jaffee, E.; Onners, B.; Piantadosi, S.; Reilly, R.T.; et al. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Hum. Gene Ther. 2004, 15, 313–337.

4. Dols, A.; Smith, J.W.; Meijer, S.L.; Fox, B.A.; Hu, H.M.; Walker, E.; Rosenheim, S.; Moudgil, T.; Doran, T.; Wood, W.; et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results. Hum. Gene Ther. 2003, 14, 1117–1123.

5. Emens, L.A.; Asquith, J.M.; Leatherman, J.M.; Kobrin, B.J.; Petrik, S.; Laiko, M.; Levi, J.; Daphtary, M.M.; Biedrzycki, B.; Wolff, A.C.; et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor - secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation. J. Clin. Oncol. 2009, 27, 5911–5918.

6. Chen, G.; Gupta, R.; Petrik, S.; Laiko, M.; Leatherman, J.M.; Asquith, J.M.; Daphtary, M.M.; Garrett-Mayer, E.; Davidson, N.E.; Hirt, K.; et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol. Res. 2014, 2, 949–961.

7. Gückel, B.; Stumm, S.; Rentzsch, C.; Marmé, A.; Mannhardt, G.; Wallwiener, D. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo. Cancer Immunol. Immunother. 2005, 54, 129–140.

8. Berd, D.; Sato, T.; Maguire, H.C.; Kairys, J.; Mastrangelo, M.J. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol. 2004, 22, 403–415.

9. Hirschowitz, E.A.; Foody, T.; Hidalgo, G.E.; Yannelli, J.R. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007, 57, 365–372.

10. Pruitt, S.K.; Kirk, A.D.; Bollinger, R.R.; Marsh, H.C.; Collins, B.H.; Levin, J.L.; Mault, J.R.; Heinle, J.S.; Ibrahim, S.; Rudolph, A.R.; et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994, 57, 363–370.

11. Lai, L.; Kolber-Simonds, D.; Park, K.W.; Cheong, H.T.; Greenstein, J.L.; Im, G.S.; Samuel, M.; Bonk, A.; Rieke, A.; Day, B.N.; et al. Production of α-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002, 295, 1089–1092.

12. Hirschowitz, E.A.; Mullins, A.; Prajapati, D.; Baeker, T.; Kloecker, G.; Foody, T.; Damron, K.; Love, C.; Yannelli, J.R. Pilot study of 1650-G: A simplified cellular vaccine for lung cancer. J. Thorac. Oncol. 2011, 6, 169–173.

13. Nemunaitis, J.; Jahan, T.; Ross, H.; Sterman, D.; Richards, D.; Fox, B.; Jablons, D.; Aimi, J.; Lin, A.; Hege, K. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 2006, 13, 555–562.

14. Nemunaitis, J.; Dillman, R.O.; Schwarzenberger, P.O.; Senzer, N.; Cunningham, C.; Cutler, J.; Tong, A.; Kumar, P.; Pappen, B.; Hamilton, C.; et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 2006, 24, 4721–4730.

15. Nemunaitis, J.; Nemunaitis, M.; Senzer, N.; Snitz, P.; Bedell, C.; Kumar, P.; Pappen, B.; Maples, P.B.; Shawler, D.; Fakhrai, H. Phase II trial of Belagenpumatucel-L, a TGF-Β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 2009, 16, 620–624.

16. Giaccone, G.; Bazhenova, L.A.; Nemunaitis, J.; Tan, M.; Juhász, E.; Ramlau, R.; Van Den Heuvel, M.M.; Lal, R.; Kloecker, G.H.; Eaton, K.D.; et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur. J. Cancer 2015, 51, 2321–2329.

17. Raez, L.E.; Cassileth, P.A.; Schlesselman, J.J.; Sridhar, K.; Padmanabhan, S.; Fisher, E.Z.; Baldie, P.A.; Podack, E.R. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 2800–2807.

18. Raez, L.E.; Walker, G.R.; Baldie, P.; Fisher, E.; Gomez, J.E.; Tolba, K.; Santos, E.S.; Podack, E.R. CD8 T cell response in a phase I study of therapeutic vaccination of advanced NSCLC with allogeneic tumor cells secreting endoplasmic reticulum-chaperone gp96-Ig-peptide complexes. Adv. Lung Cancer 2013, 2, 9–18.

19. Mitchell, M.S.; Kan-Mitchell, J.; Kempf, R.A.; Harel, W.; Shau, H.; Lind, S. Active Specific Immunotherapy for Melanoma: Phase I Trial of Allogeneic Lysates and a Novel Adjuvant. Cancer Res. 1988, 48, 5883–5893.

20. Vaishampayan, U.; Abrams, J.; Darrah, D.; Jones, V.; Mitchell, M.S. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon αlpha. Clin. Cancer Res. 2002, 8, 3696–3701.

21. Sosman, J.A.; Unger, J.M.; Liu, P.Y.; Flaherty, L.E.; Park, M.S.; Kempf, R.A.; Thompson, J.A.; Terasaki, P.I.; Sondak, V.K. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. J. Clin. Oncol. 2002, 20, 2067–2075.

22. von Euw, E.M.; Barrio, M.M.; Furman, D.; Levy, E.M.; Bianchini, M.; Peguillet, I.; Lantz, O.; Vellice, A.; Kohan, A.; Chacón, M.; et al. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease. J. Transl. Med. 2008, 6, 6.

23. Mordoh, J.; Kairiyama, C.; Bover, L.; Solarolo, E. Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients: A non randomized phase II study. Medicina (B. Aires). 1997, 57, 421–427.

24. Barrio, M.M.; De Motta, P.T.; Kaplan, J.; Von Euw, E.M.; Bravo, A.I.; Chacón, R.D.; Mordoh, J. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J. Immunother. 2006, 29, 444–454.

25. Palucka, A.K.; Ueno, H.; Connolly, J.; Kerneis-Norvell, F.; Blanck, J.P.; Johnston, D.A.; Fay, J.; Banchereau, J. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J. Immunother. 2006, 29, 545–557.

26. Berd, D. M-Vax: An autologous, hapten-modified for human cancer. Expert Rev. Vaccines 2004, 2, 335–342.

27. Ribas, A.; Camacho, L.H.; Lee, S.M.; Hersh, E.M.; Brown, C.K.; Richards, J.M.; Rodriguez, M.J.; Prieto, V.G.; Glaspy, J.A.; Oseguera, D.K.; et al. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J. Transl. Med. 2010, 8, 89.

28. Aris, M.; Bravo, A.I.; Pampena, M.B.; Blanco, P.A.; Carri, I.; Koile, D.; Yankilevich, P.; Levy, E.M.; Barrio, M.M.; Mordoh, J. Changes in the TCRβ repertoire and tumor immune signature from a cutaneous melanoma patient immunized with the CSF-470 vaccine: A case report. Front. Immunol. 2018, 9, 955.

29. Mordoh, J.; Pampena, M.B.; Aris, M.; Blanco, P.A.; Lombardo, M.; von Euw, E.M.; Keon, S. Mac; Crow, M.Y.; Bravo, A.I.; O'Connor, J.M.; et al. Phase II study of adjuvant immunotherapy with the CSF-470 vaccine plus Bacillus Calmette-Guerin plus recombinant human granulocyte macrophage-colony stimulating factor vs medium-dose Interferon alpha 2B in Stages IIB, IIC, and III cutaneous melanoma patie. Front. Immunol. 2017, 8, 625.

30. Le, D.T.; Lutz, E.; Uram, J.N.; Sugar, E.A.; Onners, B.; Solt, S.; Zheng, L.; Diaz, L.A.; Donehower, R.C.; Jaffee, E.M.; et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 2013, 36, 382–389.

31. Hopkins, A.C.; Yarchoan, M.; Durham, J.N.; Yusko, E.C.; Rytlewski, J.A.; Robins, H.S.; Laheru, D.A.; Le, D.T.; Lutz, E.R.; Jaffee, E.M. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI insight 2018, 3, 13.

32. Eric, L.; Yeo, C.J.; Lillemoe, K.D.; Biedrzycki, B.; Kobrin, B.; Herman, J.; Sugar, E.; Piantadosi, S.; Cameron, J.L.; Solt, S.; et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation. Ann. Surg. 2011, 253, 328–335.

33. Simons, J.W.; Carducci, M.A.; Mikhak, B.; Lim, M.; Biedrzycki, B.; Borellini, F.; Clift, S.M.; Hege, K.M.; Ando, D.G.; Piantadosi, S.; et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin. Cancer Res. 2006, 12, 3394–3401.

34. Small, E.J.; Sacks, N.; Nemunaitis, J.; Urba, W.J.; Dula, E.; Centeno, A.S.; Nelson, W.G.; Ando, D.; Howard, C.; Borellini, F.; et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 2007, 13, 3883–3891.

35. Van den Eertwegh, A.J.M.; Versluis, J.; Van den Berg, H.P.; Santegoets, S.J.A.M.; Van Moorselaar, R.J.A.; Van der Sluis, T.M.; Gall, H.E.; Harding, T.C.; Jooss, K.; Lowy, I.; et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol. 2012, 13, 509–517.

36. Higano, C.S.; Corman, J.M.; Smith, D.C.; Centeno, A.S.; Steidle, C.P.; Gittleman, M.; Simons, J.W.; Sacks, N.; Aimi, J.; Small, E.J. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008, 113, 975–984.

37. Doehn, C.; Böhmer, T.; Jocham, D. Technology evaluation: Onyvax-P, Onyvax. Curr. Opin. Mol. Ther. 2005, 7, 511–519.

38. Brill, T.H.; Kübler, H.R.; Randenborgh, H. V.; Fend, F.; Pohla, H.; Breul, J.; Hartung, R.; Paul, R.; Schendel, D.J.; Gansbacher, B. Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer - A phase I clinical trial. J. Gene Med. 2007, 9, 547–560.

39. Brill, T.H.; Kübler, H.R.; Pohla, H.; Buchner, A.; Fend, F.; Schuster, T.; Van Randenborgh, H.; Paul, R.; Kummer, T.; Plank, C.; et al. Therapeutic vaccination with an interleukin-2-interferon-γ-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: A phase I/II trial. Hum. Gene Ther. 2009, 20, 1641–1651.

40. Eaton, J.D.; Perry, M.J.A.; Nicholson, S.; Guckian, M.; Russell, N.; Whelan, M.; Kirby, R.S. Allogeneic whole-cell vaccine: A phase I/II study in men with hormone-refractory prostate cancer. BJU Int. 2002, 89, 19–26.

41. Schijns, V.E.J.C.; Pretto, C.; Devillers, L.; Pierre, D.; Hofman, F.M.; Chen, T.C.; Mespouille, P.; Hantos, P.; Glorieux, P.; Bota, D.A.; et al. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine 2015, 33, 2690–2696.

42. Westermann, J.; Flörcken, A.; Willimsky, G.; Van Lessen, A.; Kopp, J.; Takvorian, A.; Jöhrens, K.; Lukowsky, A.; Schönemann, C.; Sawitzki, B.; et al. Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: A clinical phase-I study. Gene Ther. 2011, 18, 354–363.

43. Smith, B.D.; Kasamon, Y.L.; Kowalski, J.; Gocke, C.; Murphy, K.; Miller, C.B.; Garrett-Mayer, E.; Tsai, H.L.; Qin, L.; Chia, C.; et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin. Cancer Res. 2010, 16, 338–347.

44. Okaji, Y.; Tsuno, N.H.; Tanaka, M.; Yoneyama, S.; Matsuhashi, M.; Kitayama, J.; Saito, S.; Nagura, Y.; Tsuchiya, T.; Yamada, J.; et al. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur. J. Cancer 2008, 44, 383–390.